Price
No data yet.
Social Signal Score
Analyst Ratings
55 analystsRevenue
$381.35M+6934.70%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael E. Severino
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 835
- Beta
- 0.20
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.02
Financials
Revenue
$381.35M+6934.7%Net Income
$-28.46MEBITDA
$1.75MFree Cash Flow
$57.03MEPS (diluted)
$-0.27Shares Outstanding (diluted)
105.93M+93.9%Operating Expenses
$201.16MCash & Debt
$878.78MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.20B | $-713.41M | $-7.13 |
| 2024 | $1.90B | $235.24M | $2.47 |
| 2023 | $1.24B | $-535.98M | $-5.80 |
| 2022 | $933.01M | $-703.49M | $-8.03 |
| 2021 | $701.89M | $-418.78M | $-5.15 |
| 2020 | $540.10M | $-554.13M | $-7.11 |
| 2019 | $380.83M | $-715.08M | $-9.71 |
| 2018 | $301.03M | $-361.92M | $-5.46 |
| 2017 | $154.58M | $-50.69M | $-0.86 |
| 2016 | $5.42M | $-267.26M | $-5.49 |
| 2015 | $1.25M | $-220.03M | $-5.20 |
| 2014 | $9.76M | $-135.79M | $-3.39 |
| 2013 | $14.22M | $-111.98M | $-3.31 |
| 2012 | $37.33M | $-121.29M | $-5.14 |
Valuation
SRPThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (10)
- Newsmarketbeat.com·13d ago·Neutral
Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance Sarepta Therapeutics NASDAQ: SRPT expects updates from its experimental neuromuscular disease programs to help shape its next phase of growth, while relying on its Duchenne muscular dystrophy business to fund development, CEO Michael Severino said at Guggenheim's Third Healthcare Innovation conference.
View source ↗ - Newsseekingalpha.com·15d ago·Positive
Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript Sarepta Therapeutics, Inc. ( SRPT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Tamara Thornton - Director of Finance, Treasury & Investor Relations Michael Severino - CEO & Director Patrick Moss - Executive VP & Chief Commercial Officer Louise Rodino-Klapac - President of Research & Development and Technical Operations Ryan Wong - Executive VP & CFO James Richardson - Executive VP & Chief Medical Offi…
View source ↗ - Newszacks.com·16d ago·Negative
SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline Sarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.
View source ↗ - Newsmarketbeat.com·16d ago·Negative
Sarepta Therapeutics Q3 Earnings Call Highlights Sarepta Therapeutics NASDAQ: SRPT raised the low end of its 2026 product revenue forecast after reporting stable demand indicators for Duchenne muscular dystrophy gene therapy ELEVIDYS and continued strength in its exon-skipping drug franchise.
View source ↗ - Newszacks.com·17d ago·Negative
Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newsbusinesswire.com·27d ago·Neutral
Sarepta Therapeutics to Present at Upcoming Investor Conferences CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9, 2026:8th Annual Wolfe Research Healthcare Conference in New York CityGuggenheim Securities 3rd Annual Healthcare Innovation Conference in BostonFireside chat: 3 p.m. ETThe presentation…
View source ↗ - Newsbusinesswire.com·58d ago·Neutral
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima, Japan. Data at WMS includes a late-breaking poster presentation on delandistr…
View source ↗ - Newsmarketbeat.com·68d ago·Neutral
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near Sarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat.
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsbenzinga.com·75d ago·Neutral
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-0.06 per share
Typical surprise -123.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.13 vs $0.08beat
- Wed, Aug 5$-0.05 vs $0.22miss
- Wed, May 6$3.16 vs $0.98beat
- Wed, Feb 25$-3.58 vs $-1.03miss
- Mon, Nov 3$-1.80 vs $-0.73miss
- Wed, Aug 6$2.02 vs $0.83beat
Estimates and results for SRPT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SRPT officers and directors.
- Bought
- —
- Sold
- $666k
0 trades
3 trades
- Mayo Stephensold
- Estepan Ian Michaelsold
- Nicaise Claudesold
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed May 7, 2025 (23d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (38d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 11, 2023 (28d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$15,001 - $50,000
- Josh Gottheimerhouse · NJ05 · disclosed Apr 20, 2023 (45d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Buy$15,001 - $50,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (24d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Dec 9, 2020 (33d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 14, 2020 (30d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jul 17, 2020 (37d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 6, 2020 (24d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Nov 15, 2019 (35d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Nov 15, 2019 (36d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed May 14, 2019 (35d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Apr 16, 2019 (36d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Mar 8, 2019 (9d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Mar 8, 2019 (10d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
